share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰制药 | 144:拟议出售证券
美股SEC公告 ·  07/30 15:31
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Inc. officer and director, Kewalramani Reshma, is set to sell 15,202 shares of common stock on July 30, 2024, with an aggregate market value of approximately $7,677,010. The shares to be sold were acquired through restricted stock vesting as part of compensation from the issuer on various dates ranging from February 17, 2023, to February 24, 2024. The total number of shares acquired through these transactions amounted to 12,202. This planned sale follows a review of securities sold in the past three months, where a total of 31,969 shares were sold for gross proceeds of $15,065,893. The notice of the upcoming sale was filed on the same date as the planned sale, with the plan for the transaction having been adopted on February 7, 2024.
Vertex Pharmaceuticals Inc. officer and director, Kewalramani Reshma, is set to sell 15,202 shares of common stock on July 30, 2024, with an aggregate market value of approximately $7,677,010. The shares to be sold were acquired through restricted stock vesting as part of compensation from the issuer on various dates ranging from February 17, 2023, to February 24, 2024. The total number of shares acquired through these transactions amounted to 12,202. This planned sale follows a review of securities sold in the past three months, where a total of 31,969 shares were sold for gross proceeds of $15,065,893. The notice of the upcoming sale was filed on the same date as the planned sale, with the plan for the transaction having been adopted on February 7, 2024.
Vertex Pharmaceuticals Inc.董事兼高级职员Kewalramani Reshma计划在2024年7月30日出售15,202股普通股,合计市值约为7,677,010美元。这些股票是作为补偿的一部分,在2023年2月17日至2024年2月24日期间,由该公司股票禁售期到期后获得的。通过这些交易获得的股票总数为12,202。这项计划出售是在审查了过去3个月出售的证券后,所做出的决定,过去3个月共出售31,969股,获得15,065,893美元的总收益。计划销售的通知与计划销售的日期相同,交易计划已于2024年2月7日通过。
Vertex Pharmaceuticals Inc.董事兼高级职员Kewalramani Reshma计划在2024年7月30日出售15,202股普通股,合计市值约为7,677,010美元。这些股票是作为补偿的一部分,在2023年2月17日至2024年2月24日期间,由该公司股票禁售期到期后获得的。通过这些交易获得的股票总数为12,202。这项计划出售是在审查了过去3个月出售的证券后,所做出的决定,过去3个月共出售31,969股,获得15,065,893美元的总收益。计划销售的通知与计划销售的日期相同,交易计划已于2024年2月7日通过。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息